HumanMAP Brochure

View Webinar

Human KidneyMAP® v 1.0

The Myriad RBM KidneyMAP panels detect early signs of renal damage which is a common problem in drug development programs. Developed in conjunction with the Predictive Safety Testing Consortium, it provides a sensitive and quantitative method to detect the earliest stages of drug-induced kidney injury. This will allow researchers to efficiently prioritize drug compounds and to accelerate decisions on exploratory and clinical testing protocols.

Sample Volume Requirements *

Click or mouse over biomarkers for more information

1. Alpha-1-Microglobulin 2. Beta-2-Microglobulin
3. Calbindin 4. Clusterin
5. Connective Tissue Growth Factor 6. Creatinine
7. Cystatin-C 8. Glutathione S-Transferase alpha
9. Kidney Injury Molecule-1 10. Microalbumin
11. Neutrophil Gelatinase-Associated Lipocalin 12. Osteopontin
13. Tamm-Horsfall Urinary Glycoprotein 14. Tissue Inhibitor of Metalloproteinases 1
15. Trefoil Factor 3 16. Vascular Endothelial Growth Factor



* Creatinine and Microalbumin in urine samples only.